Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 837-844

  Yang, Rui ^a   Sowers, Rebecca ^a   Mazza, BethAnne ^a   Healey, John H ^b   Huvos, Andrew ^a   Grier, Holcombe ^c   Bernstein, Mark ^d   Beardsley, G Peter ^e   Krailo, Mark D ^f,g   Devidas, Meenakshi ⁱ   Bertino, Joseph R ^h   Meyers, Paul A ^a   Gorlick, Richard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

^e YALE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g Children's Oncol Grp Oper Ctr   (United States)

^h ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

ⁱ Children's Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; REDUCED FOLATE CARRIER;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TRANSPORT; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

AMINO ACID SEQUENCE; BONE NEOPLASMS; CARRIER PROTEINS; CODON; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MODELS, MOLECULAR; OSTEOSARCOMA; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN CONFORMATION; TUMOR CELLS, CULTURED;

EID: 0037317006     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Meyers, P. A., and Gorlick R. Osteosarcoma. Pediatr. Clin. N. Am., 44: 973-990, 1997.
2. Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V., and Rosen, G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol., 10: 5-15, 1992.
3. Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., and Healey, J. H. Intensification of preoperative chemotherapy for osteogenic sarcoma: the results of the Memorial Sloan-Kettering (T12) protocol. J. Clin. Oncol., 16: 2452-2458, 1998.
4. Jaffe, N., Frei, E., Watts, H., and Traggis, D. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat. Rep., 62: 259-264, 1978.
5. Saeter, G., Alvegard, T. A., Elomaa, I., Stenwig, A. E., Holmstrom, T., and Solheim, O. P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J. Clin. Oncol., 9: 1766-1775, 1991.
6. Gorlick, R., Goker, E., Trippett, T., Waltham, M., Banerjee, D., and Bertino, J. R. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med., 335: 1041-1048, 1996.
7. Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyeff, Y., Mazumdar, M., Flintoff, W. F., and Bertino, J. R. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 89: 1013-1018, 1997.
8. Bacci, G., Ferrari, S., Delepine, N., Bertoni, F., Picci, P., Mercuri, M., Bacchini, P., Brach del Prever, A., Tienghi, A., Comandone, A., and Campanacci, M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J. Clin. Oncol., 16: 658-663, 1998.
9. Delepine, N., Delepine, G., Cornille, H., Brion, F., Arnaud, P., and Desbois, J. C. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res., 15: 489-494, 1995.
10. Sierra, E. E., Brigle, K. E., Spinella, M. J., and Goldman, I. D. Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells. Biochem. Pharmacol., 50: 1287-1294, 1995.
11. Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., and Gorlick, R. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res., 5: 621-627, 1999.
12. Chango, A., Emery-Fillon, N., De Courcy, G. P., Lambert, D., Pfister, M., Rosenblatt, D. S., and Nicolas, J. P. A polymorphism (80G→A) in the reduced folate carrier gene and associations with folate status and homocysteinemia. Mol. Genet. Metab., 70: 310-315, 2000.
13. 27 carriers. Clin. Cancer Res., 7: 3416-3422, 2001.
14. Gong, M., Yess, J., Connolly, T., Ivy, S. P., Ohnuma, T., Cowan, K. H., and Moscow. J. A. Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line. Blood, 89: 2494-2499, 1997.
15. Zhao, R., Gao, F., and Goldman, I. D. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochem. Pharmacol., 58: 1615-1624, 1999.
16. Brigle, K. E., Spinella, M. J., Sierra, E. E., and Goldman, I. D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J. Biol. Chem., 270: 22974-22979, 1995.
17. Zhao, R., Assaraf, Y. G., and Goldman, I. D. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J. Biol. Chem., 273: 7873-7879, 1998.
18. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., Priest, D. G., Noordhuis, P., Schornagel, J. H., Pinedo, H. M., Peters, G. J., and Assaraf, Y. G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem., 273: 30189-30198, 1998.
19. Gifford, A. J., Kavallaris, M., Madafiglio, J., Matherly, L. H., Stewart, B. W., Haber, M., and Norris, M. D. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int. J. Cancer, 78: 176-181, 1998.
20. Wong, S. C., Zhang, L., Witt, T. L., Proefke, S. A., Bhushan, A., and Matherly, L. H. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J. Biol. Chem., 274: 10388-10394, 1999.
21. Drori, S., Jansen, G., Mauritz, R., Peters, G. J., and Assaraf Y. G., Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J. Biol. Chem., 275: 30855-30863, 2000.
22. Sadlish, H., Murray, R. C., Williams, F. M., and Flintoff, W. F. Mutations in the reduced-folate carrier affect protein localization and stability. Biochem. J., 346: 509-518, 2000.
23. Tse, A., Brigle, K., Taylor, S. M., and Moran, R. G. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J. Biol. Chem., 273: 25953-25960, 1998.
24. Roy, K., Tolner, B., Chiao, J. H., and Sirotnak, F. M. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J. Biol. Chem., 273: 2526-2531, 1998.
25. Zhao, R., Assaraf, Y. G., and Goldman, I. D. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J. Biol. Chem., 273: 19065-19071, 1998.
26. Zhao, R., Sharina, I. G., and Goldman, I. D. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol. Pharmacol., 56: 68-76, 1999.
27. Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., and Urban, C. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer (Phila.), 49: 1221-1230, 1982.
28. Prasad, P. D., Ramamoorthy, S., Leibach, F. H., and Ganapathy, V. Molecular cloning of the human placental folate transporter. Biochem. Biophys. Res. Commun., 206: 681-687, 1995.
29. De Marco, P., Calevo, M. G., Moroni, A., Arata, L., Merello, E., Cama, A., Finnell, R. H., Andreussi, L., and Capra, V. Polymorphisms in genes involved in folate metabolism as risk factors for NTDs. Eur. J. Pediatr. Surg., 11 (Suppl. 1): S14-S17, 2001.
30. Shaw, G. M., Lammer, E. J., Zhu, H., Baker, M. W., Neri, E., and Finnell, R. H. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am. J. Med. Genet., 108: 1-6, 2002.
31. Nataraj, A. J., Olivos-Glander, I., Kusukawa, N., and Highsmith, W. E., Jr. Single-strand conformation polymorphism and heteroduplex analysis for gel-based mutation detection. Electrophoresis, 20: 1177-1185, 1999.
32. Jordanova, A., Kalaydjieva, L., Savov, A., Claustres, M., Schwarz, M., Estivill, X., Angelicheva, D., Haworth, A., Casals, T., and Kremensky, I. SSCP analysis: a blind sensitivity trial. Hum. Mutat., 10: 65-70, 1997.
33. Ferguson, P. L., and Flintoff, W. F. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J. Biol. Chem., 274: 16269-16278, 1999.
34. Dicker, A. P., Waltham, M. C., Volkenandt, M., Schweitzer, B. I., Otter, G. M., Schmid, F. A., Sirotnak, F. M., and Bertino, J. R. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc. Natl. Acad. Sci. USA, 90: 11797-11801, 1993.
35. Spencer, H. T., Sorrentino, B. P., Pui, C. H., Chunduru, S. K., Sleep, S. E., and Blakley, R. L. Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia (Baltimore), 10: 439-446, 1996.
36. Worm, J., Kirkin, A. F., Dzhandzhugazyan, K. N., and Guldberg, P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells. J. Biol. Chem., 276: 39990-40000, 2001.
37. Henderson, G. B., and Strauss, B. P. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Res., 50: 1709-1714, 1990.
38. Williams, F. M. R., and Flintoff, W. F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem., 270: 2987-2992, 1995.
39. Moscow, J. A., Gong, M., He, R., Sgagias, M. K., Dixon, K. H., Anzick, S. L., Meltzer, P. S., and Cowan, K. H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res., 55: 3790-3794, 1995.